Wegovy, widely popular weight-loss drug, launched in India: Price, dosage
Wegovy is a once-weekly GLP1 receptor agonist approved in India for the treatment of obesity. (Photo: Reuters) Novo Nordisk introduces Wegovy for chronic weight management in India
Wegovy contains semaglutide, a weekly injectable GLP-1 receptor agonist
Wegovy comes after its rival drug Mounjaro was launched in March
Danish pharmaceutical giant Novo Nordisk has officially launched its flagship obesity drug Wegovy (semaglutide) in India, announced Managing Director Vikrant Shrotriya on Tuesday.
Wegovy is a once-weekly GLP1 receptor agonist (separate from Ozempic), approved in India for the treatment of chronic weight management in adults who are obese or overweight with at least one weight-related health condition.
Wegovy is a once-weekly injection that contains semaglutide as its main ingredient, the same compound used in Novo Nordisk's blockbuster diabetes drug, Ozempic.
A lower-dose version of semaglutide has already been available in India since 2022 under the brand name Rybelsus, which comes in the form of a pill and is used to treat type 2 diabetes.
The price for the 0.25 mg, 0.5 mg, and 1 mg doses of Wegovy is Rs 17,345 per month, which comes to a weekly cost of approximately Rs 4,366. The 1.7 mg dose is priced at Rs 24,280 per month, while the 2.4 mg dose, the highest, costs Rs 26,015 for a month's supply.
Semaglutide works by copying the action of a natural hormone in the gut called GLP-1. This hormone sends signals to the brain that you're full, helping you eat less and regulate blood sugar.
People using this drug have been shown to lose about 15% of their body weight over a little more than a year (68 weeks).
The launch of Wegovy in India comes just before its patent for semaglutide expires next year. After that, several Indian pharmaceutical companies are expected to introduce cheaper generic versions, which could make the drug more affordable for many.
Obesity is now recognised as a major cause of serious health problems, including diabetes, heart disease, kidney and liver disorders, and even some types of cancer.
Originally set for a 2026 release, Novo Nordisk advanced Wegovy's Indian debut to 2025 in response to intense competition, especially from Eli Lilly's Mounjaro (tirzepatide), which entered the market in March 2025.
Both Wegovy and its rival drug Mounjaro (anti-obesity drug by Eli Lilly) are meant for people with a Body Mass Index (BMI) of obver 30.
Danish pharmaceutical giant Novo Nordisk has officially launched its flagship obesity drug Wegovy (semaglutide) in India, announced Managing Director Vikrant Shrotriya on Tuesday.
Wegovy is a once-weekly GLP1 receptor agonist (separate from Ozempic), approved in India for the treatment of chronic weight management in adults who are obese or overweight with at least one weight-related health condition.
Wegovy is a once-weekly injection that contains semaglutide as its main ingredient, the same compound used in Novo Nordisk's blockbuster diabetes drug, Ozempic.
A lower-dose version of semaglutide has already been available in India since 2022 under the brand name Rybelsus, which comes in the form of a pill and is used to treat type 2 diabetes.
The price for the 0.25 mg, 0.5 mg, and 1 mg doses of Wegovy is Rs 17,345 per month, which comes to a weekly cost of approximately Rs 4,366. The 1.7 mg dose is priced at Rs 24,280 per month, while the 2.4 mg dose, the highest, costs Rs 26,015 for a month's supply.
Semaglutide works by copying the action of a natural hormone in the gut called GLP-1. This hormone sends signals to the brain that you're full, helping you eat less and regulate blood sugar.
People using this drug have been shown to lose about 15% of their body weight over a little more than a year (68 weeks).
The launch of Wegovy in India comes just before its patent for semaglutide expires next year. After that, several Indian pharmaceutical companies are expected to introduce cheaper generic versions, which could make the drug more affordable for many.
Obesity is now recognised as a major cause of serious health problems, including diabetes, heart disease, kidney and liver disorders, and even some types of cancer.
Originally set for a 2026 release, Novo Nordisk advanced Wegovy's Indian debut to 2025 in response to intense competition, especially from Eli Lilly's Mounjaro (tirzepatide), which entered the market in March 2025.
Both Wegovy and its rival drug Mounjaro (anti-obesity drug by Eli Lilly) are meant for people with a Body Mass Index (BMI) of obver 30. Join our WhatsApp Channel
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Wire
an hour ago
- The Wire
Country Delight Launches Oats Beverage – A Wholesome, Affordable Plant-Based Alternative
• Expanding its portfolio with a nutritious and delicious option for health-conscious consumers New Delhi, June 24th, 2025: Country Delight has announced the launch of its all-new Oats Beverage, marking its foray into the rapidly growing plant-based drink segment. Designed for health-conscious consumers seeking a nutritious and affordable alternative, Country Delight's Oats beverage is crafted with the same commitment to purity, quality, and freshness that the brand is known for. Shift in Consumer Preference: Oat and Plant-Based Drink Gain Momentum India's widespread lactose intolerance affecting a vast number of the population meets its match in the affordable oats beverage - a smooth, lactose-free alternative that does not compromise on taste. With increasing consumer demand for plant-based alternatives, Country Delight's Oats Beverage is set to redefine the segment with its rich in taste and unmatched nutritional benefits. Made from high-quality Australian oats and free from chemical additives, preservatives, and added sugars, this product contains fiber, vitamins, and minerals, making it an ideal choice for lactose-intolerant individuals, fitness enthusiasts, and health-conscious consumers. Mr. Chakradhar Gade, CEO & Co-Founder, Country Delight, said, 'At Country Delight, we are constantly innovating to meet the evolving needs of our consumers. With the launch of Oats Beverage, we aim to provide a nutritious, plant-based alternative without compromising on taste or quality. Our mission has always been to make India live better, and this product is another step towards offering wholesome, nutritious food choices'. Key Features of Country Delight Oats Beverage Country Delight's Oats Beverage offers a range of benefits that make it a smart and wholesome choice for today's health-conscious consumers. It is naturally lactose-free, making it ideal for people with lactose intolerance who often struggle with digestive sensitivity. This oats beverage is easy on the stomach and supports better digestion thanks to the presence of soluble fiber (beta-glucan) and the absence of lactose or casein—common culprits behind bloating and discomfort. Unlike many other plant-based drinks that rely on common allergens like soy or nuts, Country Delight's Oats Beverage is free from both. The product is also free from added sugar and preservatives. It is completely unsweetened, with no artificial sweeteners, allowing consumers to enjoy a, minimally processed plant-based drink. Combining purity with quality, this oat beverage aligns with Country Delight's promise of delivering fresh, nutritious, and trustworthy products to Indian households. Country Delight's Oats Beverage is priced at Rs. 40 for a 400ml pack and will be available for order through the Country Delight app. (Disclaimer: The above content is a press release and PTI takes no editorial responsibility for the same.). This is an auto-published feed from PTI with no editorial input from The Wire.
Hindustan Times
an hour ago
- Hindustan Times
Novo Nordisk launches weight loss drug ‘Wegovy' in India
Danish pharmaceutical company, Novo Nordisk, launched its much-awaited weight loss drug 'Wegovy' in India on Tuesday. India has the third highest number of people living with overweight and obesity. (Representational image) One-weekly injectable semaglutide, Wegovy is the first and only weight management medication in India indicated for both long-term chronic weight management and reduction in risk of major adverse cardiovascular events in people living with the condition, said the company in a statement. It is being made available in five dosing strengths with an easy-to-use pen device which does away the use of syringes; therefore, can be self-administered at home. India has the third highest number of people living with overweight and obesity. Alarmingly, obesity is associated with over 200 diseases, including cardiovascular diseases, certain types of cancer, and type 2 diabetes. According to the clinical trials, the drug is shown to have 20% or more weight reduction in at least 1 in 3 individuals when used along with lifestyle interventions comprising reduced calorie diet and increased physical activity. Also, a 20% reduction in the risk of major adverse cardiovascular events, such as stroke, heart attack, and cardiovascular disease related death, when used on top of standard of care in people with established cardiovascular disease and overweight or obesity. Phase-III trial was conducted in about 3500 participants in India. 'Obesity is not just a personal health concern—it is a chronic disease and a national epidemic that India cannot afford to ignore. Recognising this, we are proud to announce that we are bringing Wegovy to Indians as a transformative and evidence-based therapeutic solution with the convenience of a world-class, state-of-the-art pen device. Additionally, we have an India-specific price with the benefit of same price for the first three dosing strengths,' said Vikrant Shrotriya, managing director, Novo Nordisk India, during the launch. According to the company statement, wegovy will be available in a once-weekly innovative pen device in five dose strengths – 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and a maintenance dosing of 2.4 mg. The price for 0.25, 0.5, and 1 mg doses is ₹ 17345 a month, and for 1.7 and 2.4mg it is ₹ 24280 and ₹ 26050 a month respectively. 'While deciding the pricing, our aim was to ensure that the real benefit gets accrued without burning a hole in the pocket. It's being launched pan-India, and it is prescription only drug,' said Shrotriya. The drug acts on key areas of the brain involved in appetite regulation and food intake thereby reducing hunger, improving satiety and reducing cravings for food, eventually inducing weight-loss, said the company statement. It also improves insulin resistance and has a beneficial effect on reduction of cardiometabolic events and risk factors. 'Semaglutide is the active ingredient in… Wegovy… It is indicated for weight management and reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight.' According to the doctors, the drug needs to be taken under medical supervision only. 'Anyone prescribed the drug has to be on a weight management programme. Indications for use include a body mass index of 30 even without comorbidities, and 27 with comorbidities. Dosage will depend on patient to patient— for weightloss, the need would be for a higher dose, and lower dose would be needed for those put on weight maintenance,' said Dr Ambrish Mithal, chairman and head of endocrinology and diabetes, Max Healthcare.
Hans India
an hour ago
- Hans India
Dire need to identify new drugs for patients with sickle cell disease: ICMR scientist
New Delhi: Identifying new drugs for patients with sickle cell disease is very important, said a senior scientist at the Indian Council of Medical Research (ICMR). Speaking to IANS, Dr. Manisha Madkaikar, Director of ICMR- Centre for Research Management and Control of Haemoglobinopathies (CRHCM) in Nagpur, shared that among many drugs only hydroxyurea therapy has so far been effective. Hydroxyurea has also been included in the National Health Mission's essential drugs list. However, the drug remains ineffective in many patients, prompting the need to find new and better treatments. 'We have known sickle cell disease for now so many decades. But it is only hydroxyurea therapy that has stood the test of time. Hydroxyurea significantly helps in improving the quality of life and complications in sickle cell disease patients,' Madkaikar said. 'However, there are some patients who do not respond to hydroxyurea therapy. Another drawback with hydroxyurea therapy is the patients have to take treatment lifelong, so that is the reason why a better drug is something which is desired, a better mode of therapy is desired,' she told IANS. The ICMR scientist said this even as the government, last week, announced an award of Rs 10 crore to develop a drug for the treatment of sickle cell disease. The tribal affairs ministry, in collaboration with the AIIMS-Delhi, will undertake a competition for the development of the drug. The selected proposal will be funded up to Rs 10 crore, said Union Minister of State for Tribal Affairs Durgadas Uikey at an event to mark World Sickle Cell Day in the national capital. Uikey also announced the institution of the Bhagwan Birsa Munda Prize for the development of a drug to treat the disease. Sickle cell disease is a genetic disorder mostly prevalent in districts with high tribal populations. About one in 86 births among STs have sickle cell disease which affects haemoglobin in red blood cells, resulting in morbidity and mortality. Madkaikar noted that there is a lot of research going on apart from bone marrow transplantation and gene therapy, which is available outside India but currently not available in India. 'We do not have any other drug which has shown promise like hydroxyurea therapy. So, there is a lot of scope or there is a lot of need for identifying such medicines which will transform the lives of patients with sickle cell disease,' the scientists said.
